Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.

COVID-19 recommendations in 23 languages for cancer patients

Christina Lau
07 Jul 2020

Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]

The recommendations, available in 23 languages, including Chinese, English, Japanese and Urdu, can be downloaded from websites of the European Cancer Patients Coalition and Hellenic Cancer Federation. [https://ecpc.org/covid-19-information/]

The recommendations cover six main areas:

1)      General considerations for cancer patients during the COVID-19 pandemic

2)      Protocols or special measures for cancer patients to avoid COVID-19 infection

3)      Action to take when someone is symptomatic

4)      Guidance on managing anxiety and stress

5)      Building trust with physicians to enhance patients’ confidence and compliance

6)      Procedures at cancer centres

Professional guidance has become highly important during this time as patients with cancer – who are at high risk of serious illness and death from COVID-19 – are facing unprecedented circumstances with concerns that may interfere with their continuity of care. The recommendations are developed to help these patients reduce the risk of contracting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); promote their safety, treatment and compliance; and ameliorate their stress and anxiety.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.